43 days ago,
Thrombosis of the venous channels in the brain is an uncommon cause of cerebral infarction relative to arterial disease, but it is an important consideration because of its potential morbidity. (See Prognosis.)
Knowledge of the anatomy of the venous system is essential in evaluating patients with cerebral venous thrombosis (CVT), since symptoms associated with the condition are related to the area of thrombosis. For example, cerebral infarction may occur with cortical vein or sagittal sinus thrombosis secondary to tissue congestion with obstruction. (See Presentation.)
Lateral sinus thrombosis may be associated with headache and a pseudotumor cerebri–like picture. Extension into the jugular bulb may cause jugular foramen syndrome, while cranial nerve palsies may be seen in cavernous sinus thrombosis as a compressive phenomenon. Cerebral hemorrhage also may be a presenting feature in patients with venous sinus thrombosis. (See Presentation.)
Imaging procedures have led to easier recognition of venous sinus thrombosis (see the images below), offering the opportunity for early therapeutic measures. (See Workup.)
Left lateral sinus thrombosis demonstrated on magn
Left lateral sinus thrombosis demonstrated on magnetic resonance venography (MRV). This 42-year-old woman presented with sudden onset of headache. Physical examination revealed no neurologic abnormalities.
View Media Gallery
Axial view of magnetic resonance (MR) venogram dem
Axial view of magnetic resonance (MR) venogram demonstrating lack of flow in transverse sinus.
View Media Gallery
The following guidelines for CVT have been provided by the American Heart Association and the American Stroke Association  :
In patients with suspected CVT, routine blood studies consisting of a complete blood count, chemistry panel, prothrombin time, and activated partial thromboplastin time should be performed.
Screening for potential prothrombotic conditions that may predispose a person to CVT (eg, use of contraceptives, underlying inflammatory disease, infectious process) is recommended in the initial clinical assessment.
Testing for prothrombotic conditions (including protein C, protein S, or antithrombin deficiency), antiphospholipid syndrome, prothrombin G20210A mutation, and factor V Leiden can be beneficial for the management of patients with CVT. Testing for protein C, protein S, and antithrombin deficiency is generally indicated 2-4 weeks after completion of anticoagulation. There is a very limited value of testing in the acute setting or in patients taking warfarin.
In patients with provoked CVT (associated with a transient risk factor), vitamin K antagonists may be continued for 3-6 months, with a target international normalized ratio of 2.0-3.0.
In patients with unprovoked CVT, vitamin K antagonists may be continued for 6-12 months, with a target international normalized ratio of 2.0-3.0.
For patients with recurrent CVT, venous thromboembolism (VTE) after CVT, or first CVT with severe thrombophilia (ie, homozygous prothrombin G20210A; homozygous factor V Leiden; deficiencies of protein C, protein S, or antithrombin; combined thrombophilia defects; or antiphospholipid syndrome), indefinite anticoagulation may be considered, with a target international normalized ratio of 2.0-3.0.
For women with CVT during pregnancy, low-molecular-weight heparin (LMWH) in full anticoagulant doses should be continued throughout pregnancy, and LMWH or vitamin K antagonist with a target international normalized ratio of 2.0-3.0 should be continued for ≥6 weeks postpartum (for a total minimum duration of therapy of 6 months).
It is reasonable to advise women with a history of CVT that future pregnancy is not contraindicated. Further investigations regarding the underlying cause and a formal consultation with a hematologist or maternal fetal medicine specialist are reasonable.
It is reasonable to treat acute CVT during pregnancy with full-dose LMWH rather than unfractionated heparin.
For women with a history of CVT, prophylaxis with LMWH during future pregnancies and the postpartum period is reasonable.
What to Read Next on Medscape
Related Conditions and Diseases
Quiz: Do You Know the Complications, Proper Workup, and Best Treatment Practices for Ischemic Stroke?
Quiz: How Much Do You Know About Hypothyroidism?
Quiz: Do You Know the Risk Factors, Symptoms, and Potential Treatments for Alzheimer Disease?
Quiz: How Much Do You Know About Hypertension?
Quiz: Test Your Knowledge of Epilepsy and Seizure-related Conditions
A 25-Year-Old Man With Painless Diplopia
NEWS & PERSPECTIVE
Temporal Trends and Factors Associated With Diabetes Mellitus Among Patients Hospitalized With Heart Failure
Watchful Waiting Tied to Worse Outcomes in LVAD Patients With Hemolysis
Age of Transfused Blood Impacts Perioperative Outcomes Among Patients Who Undergo Major Gastrointestinal Surgery
Drug Interaction Checker
Chronic Alcohol Abuse: Complications and Consequences
Most Popular Articles
According to Neurologists
DHA Supplements Linked to Less Progression to Alzheimer's in APOE4 Carriers
Heading in Soccer Linked to CNS Symptoms
'Transient Smartphone Blindness' Misdiagnosed as Multiple Sclerosis?
New Advances in Traumatic Brain Injury
FDA Clears Deflazacort (Emflaza) for DMD